Most fish oil supplement side effects are mild digestive complaints like fishy aftertaste, heartburn, nausea, and loose stools that resolve by taking capsules with meals or choosing enteric-coated formulations. At prescription doses above 1 g daily, however, large clinical trials identify a real, dose-dependent rise in new-onset atrial fibrillation and small shifts in low-density lipoprotein (LDL) cholesterol.
At Longevity Benchmark, we evaluate supplement safety by separating common physical nuisances from genuine cardiovascular and hematologic risks documented in clinical endpoint trials. The dose is what separates the two pictures. An over-the-counter capsule under 1 g of combined fatty acids sits in a different safety band from the 4 g prescription regimens where the metabolic and cardiac signals appear.
The Verdict
Digestive Nuisance Symptoms Compared with Cardiac Trial Signals
Clinical trial evidence divides fish oil adverse effects into mild digestive symptoms that carry no physical danger and dose-dependent cardiovascular signals that appear in high-intake clinical trials. The National Center for Complementary and Integrative Health (NCCIH) notes that side effects of omega-3 supplements are usually mild, citing unpleasant taste, bad breath, bad-smelling sweat, headache, and gastrointestinal symptoms like heartburn, nausea, and diarrhea.
The frequency of these complaints depends directly on the administered daily dose. In the large VITAL trial, which evaluated 25,871 participants taking 1 g daily of marine omega-3 fatty acids over a median of 5.3 years, the intervention showed no statistically significant differences in gastrointestinal symptoms, major bleeding episodes, or other serious adverse events compared with placebo.
By contrast, when daily intake rises to pharmacological levels, tolerability drops substantially. In the STRENGTH trial, which randomized 13,078 high-risk cardiovascular patients to receive either 4 g daily of omega-3 carboxylic acids or a matching corn oil control, gastrointestinal disorders occurred in 24.7% of the omega-3 group compared with 14.7% on corn oil. Drug-related adverse events were documented in 22.2% versus 12.9%, leading to study discontinuation in 10.8% of patients receiving omega-3 fatty acids compared with 8.0% taking corn oil.
Tolerability Effects and Gastrointestinal Management
Gastrointestinal side effects from fish oil supplements increase in frequency with higher daily doses, but simple formulation adjustments and meal timing reduce their occurrence. In the STRENGTH trial testing 4 g daily, diarrhea occurred in 11.9% of participants taking omega-3 carboxylic acids versus 4.9% taking corn oil. Nausea affected 3.2% versus 1.7%, dyspepsia was reported by 1.4% versus 0.6%, and abdominal discomfort occurred in 1.3% versus 0.6%.
Higher experimental doses confirm this tolerability boundary. In a six-month pilot randomized controlled trial in gout, 4 of 20 participants receiving 6.2 g daily of omega-3 fish oil reported gastrointestinal adverse effects that investigators categorized as definitely or probably related to the supplementation.
Practical adjustments resolve most of these digestive complaints. In a 2019 review published in Open Heart, DiNicolantonio and O'Keefe noted that enteric-coated fish oil helps reduce belching and fishy aftertaste. Ingesting capsules with a fat-containing meal slows gastric release and promotes emulsification. For readers assessing product quality, our best fish oil supplement guide reviews oxidation limits, while our fish oil dosage and timing guide details daily intake thresholds.
| Symptom | Trial Frequency at 4 g Daily | Control Frequency (Corn Oil) | Primary Mitigation Strategy |
|---|---|---|---|
| Diarrhea | 11.9% (STRENGTH) | 4.9% | Split daily dose across meals or reduce total grams taken |
| Nausea | 3.2% (STRENGTH) | 1.7% | Take capsules with a solid, fat-containing meal |
| Dyspepsia and heartburn | 1.4% (STRENGTH) | 0.6% | Use enteric-coated capsules or divide daily dosing |
| Abdominal discomfort | 1.3% (STRENGTH) | 0.6% | Take with food and confirm capsule freshness |
| Fishy burps and breath | Unquantified in STRENGTH; cited by NCCIH | NCCIH control data unavailable | Choose enteric-coated capsules or take with meals |
Atrial Fibrillation and Arrhythmia Risk at High Doses
High daily doses of marine omega-3 fatty acids consistently increase the risk of new-onset atrial fibrillation in randomized clinical trials, with the risk concentrating at intakes exceeding 1 g daily. A 2021 meta-analysis published in Circulation by Gencer and colleagues pooled data from 7 randomized controlled trials with 81,210 patients followed for a weighted average of 4.9 years. The researchers found that marine omega-3 supplementation was associated with a statistically significant increase in atrial fibrillation risk (hazard ratio 1.25, 95% confidence interval 1.07 to 1.46, P=0.013).
The risk elevation depended directly on the quantity consumed. In trials testing doses greater than 1 g daily, the hazard ratio reached 1.49 (95% CI 1.04 to 2.15, P=0.042), compared with a hazard ratio of 1.12 (95% CI 1.03 to 1.22, P=0.024) in trials testing 1 g daily or less. In meta-regression analysis, the hazard ratio for atrial fibrillation rose by 1.11 (95% CI 1.06 to 1.15, P=0.001) for each additional 1 g of daily omega-3 fatty acids.
Individual high-dose trials demonstrate the clinical impact of this arrhythmia signal. In the STRENGTH trial testing 4 g daily, investigator-reported new-onset atrial fibrillation was documented in 2.2% of the omega-3 carboxylic acid group versus 1.3% on corn oil (hazard ratio 1.69, 95% CI 1.29 to 2.21, nominal P < 0.001), yielding a number needed to harm of 114. The trial was halted prematurely after data crossed the prespecified futility boundary in conjunction with this increased atrial fibrillation rate.
The FDA-approved label for the pure EPA ethyl ester VASCEPA reflects these findings. In its double-blind trial of 8,179 statin-treated patients taking 4 g daily, adjudicated atrial fibrillation or flutter requiring hospitalization for 24 hours or longer occurred in 3% (127 patients) on VASCEPA compared with 2% (84 patients) on placebo (hazard ratio 1.5, 95% CI 1.14 to 1.98). Treatment-emergent atrial fibrillation adverse events in REDUCE-IT reached 5.3% versus 3.9% (risk ratio 1.35, 95% CI 1.11 to 1.65, P=0.003). In the OMEMI trial administering 1.8 g daily to elderly post-infarction patients, new atrial fibrillation occurred in 7.2% versus 4.0% (hazard ratio 1.84, 95% CI 0.98 to 3.45, P=0.06).
At lower intakes around 1 g daily, the absolute risk remains low and lacks statistical significance in individual trials. VITAL showed 469 cases among 12,542 patients on 1 g daily versus 431 among 12,577 on placebo (hazard ratio 1.09, 95% CI 0.96 to 1.24, P=0.19). In ASCEND, the main trial paper recorded 2.1% versus 1.7% (rate ratio 1.23, 95% CI 0.98 to 1.54), while linked electronic records found 7.7% versus 7.6% (rate ratio 1.02, 95% CI 0.91 to 1.15). A 2020 Cochrane review of 30 randomized trials including 77,990 participants reported little or no effect of increasing long-chain omega-3 on overall arrhythmia (risk ratio 0.99, 95% CI 0.92 to 1.06). Furthermore, the prescribing information for LOVAZA notes a possible association with more frequent recurrences of symptomatic atrial fibrillation in patients with paroxysmal or persistent arrhythmia, particularly during the first months of treatment.
Low-Density Lipoprotein Cholesterol Shifts and Fatty Acid Composition
Supplemental omega-3 fatty acids can increase low-density lipoprotein cholesterol, with the magnitude of the rise depending directly on whether the product contains docosahexaenoic acid. The prescribing information for LOVAZA, which provides 4 g daily of concentrated ethyl esters of EPA and DHA, carries a specific warning that the drug may increase LDL levels and advises clinicians to monitor lipid panels periodically.
In clinical trials in severe hypertriglyceridemia, median LDL cholesterol rose by 44.5% in patients treated with LOVAZA compared with a 4.8% decrease in the placebo group, representing a net increase of 49.3% from a baseline median of 89 mg/dL. The label notes that treatment to reduce very high triglycerides can elevate both LDL-C and non-HDL-C. Conversely, clinical trials for the EPA-only ethyl ester VASCEPA recorded a median LDL-C change of -5% on drug versus -3% on placebo (a difference of -2%, 95% CI -13 to +8), showing no LDL rise with the EPA-only form.
General consensus across health authorities reflects this biochemical distinction. In a 2012 scientific opinion, the European Food Safety Authority (EFSA) concluded that supplemental intakes of combined EPA and DHA at 2 to 6 g daily, and DHA alone at 2 to 4 g daily, induce an increase in LDL cholesterol of about 3%, whereas EPA up to 4 g daily has no significant effect on LDL. A 2019 FDA enforcement discretion letter noted that combined EPA and DHA intake may raise LDL cholesterol by approximately 2 to 4 mg/dL across studies, though results varied.
Mechanistic research clarifies why these fractions separate. In a 2020 review, Calder and Innes summarized a meta-analysis showing that EPA plus DHA supplementation produced a significant increase in LDL-C (mean difference 0.150 mmol/L, 95% CI 0.058 to 0.243). They observed that DHA increased LDL cholesterol more than EPA, an effect seen more in men than in women, and increased LDL particle size, which was not observed with EPA alone. In the STRENGTH trial, LDL cholesterol increased by 1.2% in the omega-3 carboxylic acid group compared with a 1.1% drop in the corn oil group (geometric mean ratio 1.03, 95% CI 1.01 to 1.04, P < 0.001).
The choice of comparator oil in clinical trials also complicates lipid findings. STRENGTH investigators noted that REDUCE-IT compared icosapent ethyl against mineral oil, which caused baseline increases in apolipoprotein B, LDL-C, and high-sensitivity C-reactive protein, including a greater than 30% increase in CRP. Those adverse increases did not occur with corn oil in STRENGTH. Although the FDA concluded that mineral oil could not fully explain the cardiovascular outcomes of REDUCE-IT, comparator selection influences apparent lipid changes. To contextualize these metrics, consult our lipid panel guide and our non-HDL cholesterol review.
Bleeding Evidence and the Cardiac Surgery Question
Large clinical outcome trials and comprehensive meta-analyses show that omega-3 supplements do not increase overall bleeding rates, contradicting historical assumptions about surgical hemorrhage. A 2024 study-level meta-analysis published in the Journal of the American Heart Association evaluated 11 randomized controlled trials comprising 120,643 patients. The analysis found no significant difference in pooled bleeding events between patients receiving omega-3 fatty acids and controls (rate ratio 1.09, 95% CI 0.91 to 1.31, P=0.34), with similar rates of hemorrhagic stroke, intracranial bleeding, and gastrointestinal bleeding.
A modest risk elevation appears only under specific high-dose regimens. In that same 2024 analysis, patients receiving high-dose purified EPA exhibited a 50% relative increase in bleeding risk, which corresponded to a small absolute increase of 0.6% compared with placebo. Bleeding risk correlated with EPA dose (risk difference 0.24, 95% CI 0.05 to 0.43, P=0.02), but background antiplatelet therapy did not show a statistically significant interaction (risk difference -0.01, 95% CI -0.02 to 0, P=0.056).
Prescription outcome trials document minor bleeding increments without major catastrophe. In the VASCEPA cardiovascular trial, 482 of 8,179 patients (12%) experienced a bleeding event versus 404 (10%) on placebo. Serious bleeding events occurred in 3% (111 patients) on VASCEPA versus 2% (85 patients) on placebo, with higher bleeding rates occurring in patients taking concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin. An American Heart Association (AHA) science advisory concluded that the risk of major adverse effects like bleeding and stroke was low across randomized cardiovascular trials, and STRENGTH reported no excess bleeding despite high background antiplatelet use.
In cardiac surgery, the trial evidence does not support the long-standing instruction to stop fish oil beforehand. In the OPERA trial, 1,516 patients undergoing cardiac surgery were randomized to receive 8 to 10 g of EPA and DHA over 2 to 5 days preoperatively followed by 2 g daily postoperatively, or placebo. Risk of Bleeding Academic Research Consortium (BARC) bleeding was not higher in the fish oil group (odds ratio 0.81, 95% CI 0.53 to 1.24, absolute risk difference 1.1% lower). Furthermore, total units of blood transfused were significantly lower in the fish oil group compared with placebo (mean 1.61 versus 1.92 units, p < 0.001), and higher morning-of-surgery plasma omega-3 levels correlated with lower bleeding risk. The authors concluded that these findings challenge recommendations to stop fish oil prior to cardiac surgery.
Drug Interactions and Clinical Precautionary Boundaries
Prescription fish oil formulations require monitoring when co-administered with anticoagulants, antiplatelet medications, or in patients with underlying hepatic impairment. The prescribing information for VASCEPA states that published studies demonstrate a prolongation of bleeding time with omega-3 fatty acids, though this prolongation has not exceeded normal limits or produced clinically significant bleeding episodes. Clinicians must periodically evaluate patients receiving omega-3 fatty acids alongside warfarin, direct oral anticoagulants, or antiplatelet agents.
Hepatic monitoring is explicitly required for certain prescription products. The LOVAZA prescribing information instructs physicians to monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels periodically in patients with hepatic impairment. Across trials, transaminase levels occasionally shift, warranting baseline and follow-up liver enzyme panels during therapy.
Allergy warnings represent another regulatory boundary. Both VASCEPA and LOVAZA package inserts caution that their active ingredients derive from fish oil. The manufacturers note it is unknown whether patients with established fish or shellfish hypersensitivity face an elevated risk of allergic reactions, and they advise patients to discontinue the medication and seek medical attention if allergic manifestations occur.
| Drug or Patient Category | Regulatory Warning Level | Recommended Clinical Monitoring | Documented Rationale |
|---|---|---|---|
| Anticoagulants (warfarin) and antiplatelets | FDA Prescribing Warning | Monitor clinical bleeding signs and coagulation parameters | Potential prolongation of bleeding time and higher bleeding frequency |
| Hepatic impairment | LOVAZA Prescribing Requirement | Periodic serum ALT and AST blood tests | Potential alterations in transaminase levels during therapeutic dosing |
| Fish or shellfish hypersensitivity | VASCEPA and LOVAZA Caution | Patient education on hypersensitivity symptoms | Unknown cross-reactivity risks from fish-derived oil products |
| High baseline atrial fibrillation risk | VASCEPA and LOVAZA Precaution | Pulse monitoring and ECG assessment when symptomatic | Documented increases in hospitalization for atrial flutter or fibrillation |
Gout, Glycaemic Control, and the Questions With No Data
The trials behind this page did not measure kidney outcomes, so nothing here should be read as evidence either way on renal function. What they do establish is that glycaemic control and gout are separable questions with real data behind them. Readers seeking clinical trial efficacy data across multiple health endpoints can review our fish oil efficacy summary.
Glycemic control also remains unaffected across major trials. In its 2019 enforcement discretion letter, the FDA concluded that EPA and DHA intake up to 10 g daily appears to have no adverse effect on glycemic control, as measured by fasting blood glucose and hemoglobin A1c. In the STRENGTH trial, new-onset diabetes occurred in 14.8% of the omega-3 group (286 of 1,929 patients) versus 14.2% of the corn oil group (280 of 1,975 patients), indicating no meaningful divergence.
The relationship between fish oil and gout is nuanced. In the VASCEPA trial, gout was listed as an adverse reaction occurring in at least 3% of patients and at least 1% more frequently than placebo. However, in a six-month randomized pilot trial of 40 adults with gout (serum urate 0.36 mmol/L or higher) receiving 6.2 g daily of omega-3 fish oil, there was no statistically significant difference in serum urate reduction between groups (-0.021 mmol/L on fish oil versus -0.006 mmol/L in controls). Furthermore, red-cell omega-3 concentrations correlated inversely with the total number of flares between weeks 12 and 24 (total omega-3 r = -0.75, p <= 0.001; EPA r = -0.75; DHA r = -0.76). To track urate dynamics, consult our uric acid biomarker guide.
Claims that fish oil induces acne are similarly unsupported by randomized trial data. No trial in this evidence base measured skin outcomes, so there is nothing here to explain a flare-up either.
Vitamin Toxicity Distinctions in Cod Liver Oil
Cod liver oil carries risks of fat-soluble vitamin toxicity that do not exist with standard fish body oil supplements. The NCCIH specifically warns that fish liver oils, such as cod liver oil, contain vitamins A and D in amounts that vary from product to product, and excessive intake of these fat-soluble vitamins can cause clinical toxicity.
The fatty acid concentration in cod liver oil is also substantially lower than in purified fish body oils. In a pharmacokinetic study by Dyerberg and colleagues, cod liver oil was determined to contain only 8.1% EPA and 11.0% DHA by weight. Reaching a therapeutic target of 3.2 g of combined EPA and DHA required participants to ingest 24 cod liver oil capsules daily (17 in the morning and 7 in the evening), compared with only 10 capsules for concentrated ethyl ester, re-esterified triglyceride, or free fatty acid products.
Taking high doses of cod liver oil to hit target omega-3 fatty acid levels risks ingesting dangerous quantities of preformed retinol (vitamin A). Individuals who want supplemental EPA and DHA should choose standard fish body oils or purified concentrates rather than liver oils.
- Vitamin A and D accumulation. Cod liver oil contains natural fat-soluble vitamins that accumulate in adipose and hepatic tissue, creating hypervitaminosis risks at high intake levels.
- Low fatty acid concentration. With only 8.1% EPA and 11.0% DHA by weight in trial analyses, cod liver oil requires excessive capsule volumes to achieve pharmacological omega-3 doses.
- Intended nutritional role. Fish liver oils function as whole-food vitamin supplements rather than concentrated sources of therapeutic eicosapentaenoic acid and docosahexaenoic acid.
Clinical Warning Signs and Adverse Event Reporting
The FDA's instruction for a suspected supplement reaction is the same whatever the symptom: contact or see your health care provider immediately. It does not ask the reader to decide first whether the effect is serious, and neither does this page.
The FDA provides clear guidance for handling suspected supplement toxicity. According to official FDA supplement safety guidance, any consumer who believes they have suffered a harmful effect or illness from a dietary supplement should contact their healthcare provider immediately. Following medical care, patients and clinicians can submit a formal adverse event report through the FDA's Safety Reporting Portal, which the agency's dietary supplement guidance links from.
Our safety assessment would change if future randomized controlled trials demonstrate that lower over-the-counter doses (under 500 mg daily) carry measurable atrial fibrillation risks, or if independent trials demonstrate that purified fish oil causes renal impairment.
To manage your risk today, check the product label on your fish oil supplement, calculate the exact combined milligrams of EPA and DHA per serving, and review your baseline heart rhythm and lipid panel with your prescribing clinician before escalating your daily dose.
Frequently Asked Questions
What are the side effects of fish oil supplements?
Common side effects of fish oil supplements are mild digestive issues, including heartburn, nausea, loose stools, bad breath, and fishy-tasting belches. In the large STRENGTH trial testing 4 g daily of omega-3 carboxylic acids, gastrointestinal disorders occurred in 24.7% of participants versus 14.7% on corn oil, with diarrhoea affecting 11.9% compared to 4.9%. Serious adverse effects are primarily dose-dependent. In clinical trials testing doses above 1 g daily, fish oil is associated with an increased risk of new-onset atrial fibrillation. Certain products containing docosahexaenoic acid (DHA) can also raise low-density lipoprotein (LDL) cholesterol, while high-dose purified eicosapentaenoic acid (EPA) carries a modest increase in absolute bleeding risk. Standard retail doses below 1 g daily rarely cause serious complications.
Does fish oil cause atrial fibrillation?
Yes, clinical trials confirm that fish oil increases the risk of new-onset atrial fibrillation at high daily doses. A meta-analysis of seven randomized controlled trials published in Circulation by Gencer and colleagues found a higher rate of atrial fibrillation on omega-3 (hazard ratio 1.25, 95% CI 1.07 to 1.46). The effect tracked the dose: trials testing more than 1 g daily gave a hazard ratio of 1.49 (95% CI 1.04 to 2.15), while trials testing 1 g daily or less gave 1.12 (95% CI 1.03 to 1.22). In the STRENGTH trial testing 4 g daily, new-onset atrial fibrillation occurred in 2.2% of patients versus 1.3% on corn oil (hazard ratio 1.69), prompting the trial to stop early. Anyone with a history of arrhythmia should consult their physician before taking fish oil.
Can fish oil raise your LDL cholesterol?
Fish oil can raise low-density lipoprotein (LDL) cholesterol, particularly when formulations contain docosahexaenoic acid (DHA). In trials of the prescription medication LOVAZA, which combines EPA and DHA for severe hypertriglyceridemia, median LDL cholesterol rose 44.5% compared to a 4.8% drop on placebo. The European Food Safety Authority noted that combined EPA and DHA at 2 to 6 g daily, or DHA alone at 2 to 4 g daily, induces an average 3% increase in LDL cholesterol. By contrast, purified EPA formulations like VASCEPA showed a 5% drop in median LDL cholesterol in trials, with no net increase compared to placebo. A 2020 review by Calder and Innes confirmed that DHA raises LDL cholesterol and increases particle size more than EPA.
Is fish oil a blood thinner?
Fish oil is not a pharmaceutical blood thinner, but high doses can modestly prolong bleeding time through platelet effects. A 2024 meta-analysis of 11 clinical trials encompassing 120,643 patients published in the Journal of the American Heart Association found no difference in overall bleeding events between omega-3 supplements and control groups. When examining high-dose purified EPA, the researchers found a 50% relative increase in bleeding, but this equated to an absolute risk increase of only 0.6%. The FDA label for VASCEPA warns that bleeding events occurred in 12% of patients compared to 10% on placebo, with serious bleeding in 3% versus 2%. The risk was higher in patients taking concomitant anticoagulants such as warfarin or aspirin.
Do I need to stop fish oil before surgery?
Modern clinical evidence challenges the routine practice of discontinuing fish oil before surgery, though patients must follow their surgeon's specific instructions. In the OPERA clinical trial of 1,516 cardiac surgery patients, administering 8 to 10 g of EPA and DHA over 2 to 5 days preoperatively followed by 2 g daily postoperatively did not increase bleeding compared with placebo. The odds ratio for bleeding was 0.81, and patients taking fish oil required significantly fewer blood transfusions than those on placebo, averaging 1.61 units versus 1.92 units. Higher blood omega-3 levels on the morning of surgery were associated with lower bleeding risks. However, prescription labels still recommend monitoring when fish oil is combined with antithrombotic therapies.
Can fish oil cause heartburn or diarrhoea?
Yes, heartburn, indigestion, and diarrhoea are recognized side effects of fish oil supplements. In the STRENGTH trial evaluating 4 g daily of omega-3 carboxylic acids against corn oil, diarrhoea occurred in 11.9% of participants versus 4.9% on control, while dyspepsia occurred in 1.4% versus 0.6%. According to the National Center for Complementary and Integrative Health, these gastrointestinal symptoms are generally mild and dose-dependent. Taking fish oil capsules alongside fat-containing meals slows digestion and aids absorption, which helps reduce gastric distress. Additionally, a 2019 review by DiNicolantonio and O'Keefe noted that using enteric-coated capsules can help bypass the stomach, reducing indigestion, heartburn, and the recurrence of fishy aftertaste and belching.
Is fish oil bad for your kidneys?
The trials this page draws on did not measure kidney outcomes, so there is no evidence here to answer the question in either direction. The FDA has concluded that supplements providing no more than 5 g a day of combined EPA and DHA are safe and lawful, but that conclusion rests on bleeding and glycaemic data, not renal data. Anyone with existing chronic kidney disease should take that question to their nephrologist rather than to a trial summary.
Why do fish oil supplements make you smell?
Fish oil supplements can occasionally cause bad breath, unpleasant skin odor, or fishy-smelling sweat due to the excretion of volatile fatty acid metabolites. The National Center for Complementary and Integrative Health lists bad breath and bad-smelling sweat as known mild side effects of omega-3 supplements. When the body digests high quantities of marine oils, volatile lipid breakdown products and secondary oxidation compounds can be expelled through breath exhalations and perspiration. Using fresh, high-quality supplements stored in cool, dark conditions reduces the presence of oxidized lipids that contribute to odor. Switching to enteric-coated capsules or dividing a large daily dose into smaller morning and evening portions can also minimize systemic odor.